ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0065

Altered Expression of Several miRNAs in Axial Spondyloarthritis Patients with High Disease Activity

Jiri Baloun1, Kristyna Bubova1, Aneta Pekacova1, Monika Gregova2, Sarka Forejtova1, Jana Horinkova1, Michal Tomcik3, Jindriska Gatterova1, Jiri Vencovsky1, Karel Pavelka3 and Ladislav Senolt3, 1Institute of Rheumatology, Prague, Czech Republic, 2Rheumatology Institute Prague, Prague, Czech Republic, 3Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

Meeting: ACR Convergence 2021

Keywords: Ankylosing spondylitis (AS), Disease Activity, Micro-RNA, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Recent studies have shown that microRNAs (miRNAs) play a role in various disorders, including immune mediated inflammatory diseases. Therefore, we studied relationship between miRNA profiles, disease activity and selected clinical manifestations of axial spondyloarthritis (axSpA).

Methods: We studied the whole miRNome in peripheral blood mononuclear cells (PBMC) of patients with non-radiographic (n=38) and radiographic (n=38) axSpA. The miRNA expression was profiled by massive parallel sequencing. The expression of particular miRNAs was correlated with disease activity (ASDAS, BASDAI and CRP) and selected clinical manifestations (e.g. uveitis). Sequencing data were analysed using DESeq2 algorithm, which additionally assessed the relationship of miRNA expression with BASDAI or the presence of uveitis, and the relationship with ASDAS and CRP were analysed using generalized linear modelling with negative binomial assumption (GLM-NB).

Results: Although DESeq2 did not reveal associations between miRNA expression, BASDAI or uveitis; the expression of several miRNAs correlated with the levels of CRP (p < 0.05). The pairwise comparison of ASDAS levels by Dunnett`s test revealed that 14 miRNAs were significantly different in axSpA patients with high and very high disease activity compared to patients with inactive disease. The pathway enrichment analysis by MIENTURNET revealed a list of pathways, with emphasis on interleukin (e.g., IL-4, IL-6, IL-10), JAK-STAT and NOTCH signalling pathways, in which dysregulated miRNAs are potentially involved. Additionally, the screening revealed that miR-1246 was differently expressed between radiographic and non-radiographic axSpA patients.

Conclusion: Our results revealed altered expression of several miRNAs in patients with high disease activity of axSpA, which may affect their target genes associated with pathogenesis of the disease.

This work was supported by the project MHCR 023728 and AZV No. 17-33127A S.


Disclosures: J. Baloun, None; K. Bubova, None; A. Pekacova, None; M. Gregova, None; S. Forejtova, None; J. Horinkova, None; M. Tomcik, None; J. Gatterova, None; J. Vencovsky, AbbVie, 1, 6, Boehringer Ingelheim, 2, Eli Lilly, 1, 6, Gilead, 1, Octapharma, 1, Biogen, 6, MSD, 6, Pfizer, 6, Roche, 6, Sanofi, 6, UCB, 6, Novartis, 6, Werfen, 6; K. Pavelka, Abbvie, 6, UCB, 6, MSD, 6, Roche, 6, Pfizer, 6, Eli Lilly, 6, Egis, 6, Biogen, 6, Pfizer, 6; L. Senolt, None.

To cite this abstract in AMA style:

Baloun J, Bubova K, Pekacova A, Gregova M, Forejtova S, Horinkova J, Tomcik M, Gatterova J, Vencovsky J, Pavelka K, Senolt L. Altered Expression of Several miRNAs in Axial Spondyloarthritis Patients with High Disease Activity [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/altered-expression-of-several-mirnas-in-axial-spondyloarthritis-patients-with-high-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/altered-expression-of-several-mirnas-in-axial-spondyloarthritis-patients-with-high-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology